5:46 PM
 | 
Apr 02, 2014
 |  BC Extra  |  Top Story

FDA approves Stallergenes' Oralair

FDA approved Oralair from Stallergenes S.A. (Euronext:GENP) to treat grass pollen-induced allergic rhinitis with or without conjunctivitis in people aged 10-65...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >